XOMA Royalty (XOMA) EPS (Weighted Average and Diluted) Growth (3y) (2013 - 2026)
XOMA Royalty (XOMA) EPS (Weighted Average and Diluted) Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
59.54% |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
22,777.33% |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
1,857.10% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
41.33% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
14.33% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
XOMA Royalty |
5.52 Mn |
-60.56 Mn |
- |
29.53% |
| Date | Value |
|---|
| Mar 31, 2026 |
29.53% |
| Dec 31, 2025 |
34.00% |
| Sep 30, 2025 |
51.22% |
| Jun 30, 2025 |
41.45% |
| Mar 31, 2025 |
29.81% |
| Dec 31, 2024 |
-30.19% |
| Sep 30, 2024 |
-46.09% |
| Jun 30, 2024 |
67.62% |
| Mar 31, 2024 |
-7.10% |
| Dec 31, 2023 |
-50.61% |
| Sep 30, 2023 |
-81.71% |
| Jun 30, 2023 |
-21.37% |
| Mar 31, 2023 |
-25.99% |
| Dec 31, 2022 |
-9.31% |
| Sep 30, 2022 |
-63.86% |
| Jun 30, 2022 |
-4.09% |
| Mar 31, 2022 |
-52.17% |
| Dec 31, 2021 |
101.89% |
| Sep 30, 2021 |
2.49% |
| Jun 30, 2021 |
-10.46% |
